None listed
Conditions
Brief summary
In patientents with oesophageal cancer or cancer of the gastro-oesophageal junction, Sentinel Lymph Node Biopsy (SLNB) has the potential to identify patients without lymph node metastases and thus improve the staging accuracy. The impact of neoadjuvant treatment on the lymphatic drainage of oesophageal cancers and subsequently the SLNB procedure in this tumour type has not been well studied. This study aims to evaluate changes in lymphatic drainage patterns of the tumour in patients with cancer of the oesophagus or gastro-oesophageal junction (GOJ) using Sentinel Lymph Node (SLN) hybrid SPECT/CT lymphoscintigraphy before and after neoadjuvant chemo-radiotherapy.
Interventions
Patients undergoing a well defined regimen of neoadjuvant radio-chemotherapy consisting of three cycles of intrevenously administered Cisplatin/Oxaliplatin-5-FU and external beam radiation therapy with a total dose of 40 Gy given in fractions. Patientents will undergo hybrid SPECT/CT lymphoscintigraphy by means of endoscopically guided intratumoral injection of radiocolloid (4 X 0.5 mL in total of 60 MBq 99mTc-nanocoll (GE Healthcare Srl., Milan, Italy)). Patients undergo this procedure the wee
Patients undergoing a well defined regimen of neoadjuvant radio-chemotherapy consisting of three cycles of intrevenously administered Cisplatin/Oxaliplatin-5-FU and external beam radiation therapy with a total dose of 40 Gy given in fractions. Patientents will undergo hybrid SPECT/CT lymphoscintigraphy by means of endoscopically guided intratumoral injection of radiocolloid (4 X 0.5 mL in total of 60 MBq 99mTc-nanocoll (GE Healthcare Srl., Milan, Italy)). Patients undergo this procedure the week prior to and once again immediatly following conclusion of neoadjuvant therapy.
Sponsors
Karolinska University Hospital
Study design
Allocation
Non-randomised trial
Primary purpose
Diagnosis
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients eligible for inclusion had to have histologically verified, clinical stage T2-T3, any N-stage, M0 cancer of the oesophagus or GE-junction planned for esophagectomy following neoadjuvant chemo radiotherapy. Patient age less than or equal to 75 years, physical performance status allowing esophagectomy and with a performance status, renal and haematological status permitting chemotherapy.
Exclusion criteria
Poor performance, renal and hematoloical status.
Outcome results
None listed